Samsara BioCapital GP, LLC
10% Owner

Samsara BioCapital GP, LLC insider trades: Kalaris Therapeutics (KLRS) stock purchases

10% Owner, Kalaris Therapeutics Last trade Dec 18, 2025 8 Form 4 filings
$0
Sold, last 12 months
0 sales
$5.0M
Bought, last 12 months
1 buy
7
Open-market trades
since 2023
6
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Samsara BioCapital GP, LLC reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Dec 18, 2025KLRS↑ Buy$5.0M
Mar 13, 2025MLYS↑ Buy$8.1M
Nov 26, 2024NGNE↑ Buy$1.3M
May 30, 2024CRGX↑ Buy$5.0M
Feb 12, 2024MLYS↑ Buy$7.5M
Nov 14, 2023CRGX↑ Buy$10.0M
Oct 16, 2023SRRK↑ Buy$15.0M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other KLRS insiders

Open-market trades in the last 12 months

About Samsara BioCapital GP, LLC's insider trades

Samsara BioCapital GP, LLC is a 10% owner of Kalaris Therapeutics (KLRS). Since Oct 16, 2023, it has reported 7 open-market purchases worth $51.9M and no sales on SEC Form 4. In the last 12 months: 1 buy ($5.0M).

Its filings also include other transactions (1 filing), grants and awards (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KLRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.